@article{79d9fcab7c414d789731e0723dfeab7b,
title = "Diagnosis of pulmonary hypertension",
abstract = "A revised diagnostic algorithm provides guidelines for the diagnosis of patients with suspected pulmonary hypertension, both prior to and following referral to expert centres, and includes recommendations for expedited referral of high-risk or complicated patients and patients with confounding comorbidities. New recommendations for screening high-risk groups are given, and current diagnostic tools and emerging diagnostic technologies are reviewed.",
author = "Adaani Frost and David Badesch and Gibbs, {J. Simon} and Deepa Gopalan and Dinesh Khanna and Alessandra Manes and Ronald Oudiz and Toru Satoh and Fernando Torres and Adam Torbicki",
note = "Funding Information: Conflict of interest: A. Frost reports personal fees and non-financial support (travel and lodging for attendance and participation in the 6th WSPH) from Actelion, Gilead, United Therapeutics and Bayer, honoraria for presentations from Gilead, and honoraria for participation in an end-point adjudication committee for an FDA-approved study from United Therapeutics, during the conduct of the study; and personal fees (honoraria and travel and lodging for presentations at meetings) from Actelion Pharmaceuticals, outside the submitted work. D. Badesch reports grants and personal fees (as steering committee member and site investigator) from Acceleron, Complexa, Bellerophon and Liquidia, grants, personal fees and advisory board work from Actelion, is a long-term stock holder of Johnson and Johnson, grants and personal fees (as advisory board member and site investigator) from Arena, Gilead and United Therapeutics/Lung LLC, personal fees for consultancy from Respira, grants and personal fees (as site investigator, advisory board member and consultant) from Bayer, outside the submitted work. J.S.R. Gibbs reports grants and personal fees from Actelion, GSK, MSD and Pfizer, personal fees from Arena, Bayer, Bellerophon, Complexa and Acceleron, and grants from United Therapeutics, during the conduct of the study. D. Gopalan has nothing to disclose. D. Khanna reports personal fees from Actelion, Bayer, Boehringer Ingelheim, Chemomab, Corbus, Covis, Cytori, EMD Sereno, Genentech/Roche, Gilead, GSK, Sanofi-Aventis and UCB Pharma; grants from Bayer, Boehringer Ingelheim, Genentech/Roche, Pfizer and Sanofi-Aventis; and has stock options with Eicos Sciences, Inc. He was also supported by the NIH/NIAMS (K24 AR063120). A. Manes reports grants and personal fees from Actelion, and grants from Bayer and Pfizer, outside the submitted work. R. Oudiz reports grants and consulting and speaker fees from Actelion, Gilead and United Therapeutics, grants from Aadi and GSK, consulting fees from Complexa, Acceleron and Medtronic, and grants and consulting fees from Arena and Reata, outside the submitted work. T. Satoh has nothing to disclose. F. Torres reports personal fees from Actelion, Bayer, Reata and Arena, and grants from Gilead, United Therapeutics, Medtronic, Eiger and Bellerophon, during the conduct of the study. A. Torbicki reports personal fees from Actelion, AOP Orphan Pharmaceutics, Bayer and MSD, and non-financial support from Pfizer, outside the submitted work; and is also a chairperson of the Foundation for Pulmonary Hypertension, which receives donations from outside parties to support its activities. The chair receives no financial compensation for this function. Publisher Copyright: Copyright {\textcopyright} ERS 2019. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.",
year = "2019",
month = jan,
day = "1",
doi = "10.1183/13993003.01904-2018",
language = "English (US)",
volume = "53",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",
}